

> Suspect in 病人 with venous or arterial thrombosis at young age or unusual locations, recurrent thromboses or pregnancy loss, or ⊕ FHx


# HYPERCOAGULABLE STATES

_Suspect in 病人 with venous or arterial thrombosis at young age or unusual locations, recurrent thromboses or pregnancy loss, or_ ⊕ _FHx_

![](https://i.imgur.com/iuA7jyl.jpg)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Vascular Beds Affected by Inherited and Acquired Hypercoagulable States</b></p></td></tr><tr><td></td><td><p><b>Venous</b></p></td><td><p><b>Venous and Arterial</b></p></td></tr><tr><td><p><b>Inher.</b></p></td><td><p><b>Factor V Leiden</b></p><p>Prothrombin mutation ↓ protein C, S or AT III</p></td><td><p>Hyperhomocysteinemia (inherited or acquired)</p><p>Dysfibrinogenemia</p></td></tr><tr><td><p><b>Acquired</b></p></td><td><p>Stasis: immobilization, surgery, CHF</p><p>Malignancy</p><p>Hormonal: OCPs, HRT, tamoxifen, pregnancy</p><p>Nephrotic syndrome</p></td><td><p>Platelet defects: myeloproliferative disorders, HIT, PNH (although venous &gt; arterial)</p><p>Hyperviscosity: polycythemia vera, Waldenström’s macroglobulinemia, sickle cell, acute leukemia</p><p>Vessel wall defects: vasculitis, trauma, foreign bodies</p><p>Others: <b>antiphospholipid syndrome</b>, IBD</p></td></tr></tbody></table>

Diagnostic evaluation (not routinely required for initial VTE; _NEJM_ 2017;377:1177)

• APC resistance screen; prothrombin PCR test; functional assays for proteins C and S, ATIII; homocysteine level; factor VIII levels; anticardiolipin and lupus anticoagulant Ab. Also consider nephrotic syndrome, PNH (esp. if mesenteric thrombus).

• Consider _JAK2_ mutation testing if suspect MPN or splanchnic thrombosis

• Proteins C & S and ATIII levels are affected by acute thrombosis and anticoagulation ∴ levels best assessed ≥2 wk after completing anticoagulation course

• Age-appropriate malignancy screening (occult cancer in ~4% of initial unprovoked VTE; no benefit of routine abd/pelvis CT; _NEJM_ 2015;373:697)

治療

• Asx with inherited risk factor: consider prophylactic anticoag. if develops acquired risk factor

• Thrombosis with inherited risk factor: see “Venous Thromboembolism”

Antiphospholipid syndrome (APS) (_NEJM_ 2018;398:2010)

• 定義: dx requires ≥1 臨床& ≥1 laboratory criteria

Clinical: thrombosis (any) or complication of pregnancy (≥3 spont. abortions before 10 wk or ≥1 fetal loss after 10 wk or premature birth before 34 wk)

Laboratory: ⊕ moderate–high titer anticardiolipin (ACL), ⊕ lupus anticoagulant (LA), or ⊕ β2\-glycoprotein-I (β2\-GP-I) Ab, on ≥2 occasions, at least 12 wk apart

• Clinical: **DVT/PE/CVA**, **recurrent fetal loss**, ↓ **plts**, hemolytic anemia, livedo reticularis; “**catastrophic APS**”: ≥3 organ systems in <1 wk with ⊕ APLA & tissue microthrombi; 44% mortality (_Arth Rheum_ 2006;54:2568); Rx with plasmapheresis, rituximab

• **Antiphospholipid antibodies (APLA)**

✔ _if: SLE, age_ <_40 y & arterial thromb, recurrent venous thromb, spontaneous abortion_

ACL: Ab against cardiolipin, a mitochondrial phospholipid; IgG more specific than IgM

LA: Ab that prolongs phospholipid-dependent coagulation reactions; ∴ ↑ **PTT** that does _not_ correct with mixing study but does correct with excess phospholipids or platelets; PT not affected b/c the reaction contains much more phospholipid

β2\-GP-I: Ab against β2\-glycoprotein-I, IgG or IgM (uncertain role of Abs in pathogenesis)

False ⊕ VDRL: nontreponemal test for syphilis in which cardiolipin is part of Ag complex

Risk of thromboembolic phenomena may increase with titer of APLs

• 原因: primary (idiopathic) or secondary due to **autoimmune syndromes** (eg, SLE), **malignancy**, **infections**, drug reactions

• 治療: UFH/LMWH → warfarin (lifelong for most 病人)

Rivaroxaban inferior to warfarin in triple positive (⊕ ACL, LA, & β2\-GP) (_Blood_ 2018;132:1365)

Initial _venous thrombosis:_ INR 2–3 (_NEJM_ 2003;349:1133; _J Thromb Haemost_ 2005;3:848)

Initial _arterial thrombosis:_ typically INR 2–3 + ASA 81 mg/d

_Recurrent thrombosis_ on warfarin: consider INR 3–4 vs. LMWH or fondaparinux (_Arth Rheum_ 2007;57:1487)
